PhaseBio Pharmaceuticals, Inc. (PHAS)
SG&A Expense Growth
14.27%
Quarterly · Period ending:
PHAS SG&A Expense Growth
Latest reported14.27%period ending
Latest reported14.27%period ending
PHAS Quarterly SG&A Growth (QoQ) (0.00% → 14.27%)
Latest values, visible window
High-resolution chart · PNG
PHAS sg&a expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | SG&A Expense Growth |
|---|---|
| 14.2679% | |
| 135.8557% | |
| -390.791% | |
| -4.472% | |
| 20.9799% | |
| -7.8649% | |
| 17.3927% | |
| -5.1203% | |
| 2.6274% | |
| -13.7592% | |
| 30.6814% | |
| 16.5973% | |
| 3.7997% | |
| 3.3467% | |
| 112.2159% | |
| 15.1581% | |
| 42.6128% | |
| 2.3885% | |
| 11.1504% | |
| 0% |